RecruitingNCT06321939

Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

Sponsor

Hunan Cancer Hospital

Enrollment

50 participants

Start Date

Jan 11, 2024

Study Type

OBSERVATIONAL

Conditions

Nasopharyngeal Carcinoma Herpesvirus 4, Human

Summary

The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients. the investigators aim to conduct plasma EBV DNA counting by next generation sequencing (NGS) in non-metastatic NPC patients on their diagnose, after two cycles of induction chemotherapy (IC), and 4-8 weeks after definitive radiotherapy. The investigators aim to explore whether sequencing-based counting is better than PCR analysis in plasma EBV-DNA surveillance, so as to monitoring tumor responses to treatment and for guiding individualized treatment adaptation in the future.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether measuring Epstein-Barr virus (EBV) DNA in the blood can help predict how nasopharyngeal cancer (a type of head and neck cancer) responds to treatment. Researchers want to use this blood test to personalize treatment intensity — reducing therapy for those who respond well early. **You may be eligible if:** - You have been newly diagnosed with nasopharyngeal cancer (WHO type II or III) that has not yet been treated - Your cancer has not spread to distant parts of the body - You are 18 years or older - Your physical fitness score (ECOG) is 0 or 1 - You are receiving standard treatment (radiation with or without chemotherapy) - Your blood EBV DNA levels were detectable before and early in treatment - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if:** - Your cancer has already spread to distant organs - Your EBV DNA was undetectable in blood before or early in treatment - Your blood counts, liver, or kidney function are too low Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.